The CAPILLARYS 3 OCTA is the most recent Sebia automated capillary electrophoresis system.
The CAPILLARYS 3 OCTA has the great heritage of CAPILLARYS 2 FLEX-PIERCING, with countless enhancements, based on the same technology as CAPILLARYS 3 TERA.
The CAPILLARYS 3 OCTA offers a broad assay menu in myeloma, diabetes, hemoglobinopathies and chronic alcohol abuse.
The CAPILLARYS 3 OCTA shares the same reagent and consumables as the other CAPILLARYS 3 instruments, allowing the lab to adopt the most relevant platforms, mixing CAPILLARYS 3 OCTA, TERA, TERA TLA and TERA MC configurations to match exactly the needs of their organization. This flexibility also allows the lab to evolve easily by scaling up the Sebia solution.
CAPILLARYS 3 can run up to 7 techniques, automated technique changes are enabled via pre-set switch racks, which allows users to load up to 120 samples with diverse tests simultaneously.
Sharing the same technical platform and reagent line, laboratories can mix the different CAPILLARYS 3 platforms to meet their individual needs in production capacity, in addition to the large automated capillary electrophoresis menu.
4 open positions for main reagents, temperature-controlled section for secondary reagent (antisera), automated reagent identification, change buffer without interrupting the testing.
Delivered with each Sebia’s instrument, the PHORESIS software allows laboratory to manage the instrument results providing a very flexible solution.
Sample types: whole blood, urine, serum
With 8 capillaries, the CAPILLARYS 3 OCTA reduces hands-on-time and offers a large loading capacity with 120 samples (15 racks).
Throughput (tests/hour)*
PROTEIN(E) 6 (serum) 79
PROTEIN(E) 6 (urine) 70
IMMUNOTYPING (serum or urine) 9
Hb A1c 43
HEMOGLOBIN(E) 45
CDT 49
* Using Software version 9.30
High throughput Serum Protein Electrophoresis, with high resolution results.
High throughput Urine Protein Electrophoresis, with high resolution results.
Fully automated monoclonal proteins identification by Capillarys electrophoresis.
The high-resolution method for hemoglobin disorders screening.
The most reliable chronic alcohol abuse marker.
Interview between Sebia and M. Jean Deenmamode, CDT IFCC Working Group Chair
Understand in 2 minutes how capillary electrophoresis works, and why it gives such high and clear resolution in lab testing.
Understand your needs and constraints to provide you with the most suitable and integrated solution.
Improve your lab performance by optimizing your Sebia solutions.
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
Educational Webinar with Dr. Julien GUILLEMAUD
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
Educational Webinar with David G. Grenache, PhD, D(ABCC)
Chief Scientific Officer, TriCore Reference Laboratories
Educational Webinar with Dr. Mark Zaydman from Washington University School of Medicine in St. Louis, MO
Educational Webinar Pr Simone Scarlata
Educational Webinar Dr. Cornelia L. Harteveld from Leiden University Medical Center
Educational Webinar with Jason EYRE
Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL
CDT is a sensitive and specific marker of chronic alcohol abuse, used in several contexts and notably including forensic settings, industries, clinical applications.
Educational Webinar with Prof. Giovanni PALLADINI, PhD
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
Educational Webinar with Dr Nadia Maria Porpiglia
Educational Webinar with Dr. Ilaria Ferrarotti
Educational Webinar with Dr. Barbara De la Salle
European Myeloma Network Meeting – EMN 2024
Sebia booth: #9
IFCC CDT-Working Group standardized the CDT measurement.
Article from Jean Deenmamode, IFCC CDT working group chair in CLI magazine.
Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results depending on the method of analysis used. Therefore, it is important to know the limitations of the method used for HbA1c determination.
The EurA1c trial, organized yearly, investigates the performance of HbA1c assays across countries and manufacturers.
This article assesses the performances of the different manufacturers and technologies (HPLC and CE) for Hb A2 measurement using both International Reference Reagent for HbA2 (WHO IRR 89/666) and analysis of three whole blood specimens over a range of HbA2, distributed to 56 laboratories located in 14 different countries.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.